Statera BioPharma (STU:7CB) LT-Debt-to-Total-Asset : 0.05 (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Statera BioPharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Statera BioPharma's long-term debt to total assests ratio for the quarter that ended in Sep. 2022 was 0.05.

Statera BioPharma's long-term debt to total assets ratio declined from Sep. 2021 (0.14) to Sep. 2022 (0.05). It may suggest that Statera BioPharma is progressively becoming less dependent on debt to grow their business.

Statera BioPharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for Statera BioPharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Statera BioPharma LT-Debt-to-Total-Asset Chart

Statera BioPharma Annual Data

Trend

Dec19

Dec20

Dec21

LT-Debt-to-Total-Asset

0.07

0.54

Statera BioPharma Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial						0.14	0.54	0.06	0.06	0.05

Statera BioPharma LT-Debt-to-Total-Asset Calculation

Statera BioPharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

LT Debt to Total Assets (A: Dec. 2021 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2021 )	/	Total Assets (A: Dec. 2021 )
	=	10.116	/	18.735
	=

Statera BioPharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2022 is calculated as

LT Debt to Total Assets (Q: Sep. 2022 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2022 )	/	Total Assets (Q: Sep. 2022 )
	=	0.693	/	12.876
	=

Statera BioPharma (STU:7CB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Statera BioPharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Statera BioPharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Statera BioPharma (STU:7CB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Statera BioPharma Inc (STU:7CB) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

4333 Corbett Drive, Suite 1082, Fort Collins, CO, USA, 80525

Website

https://www.staterabiopharma.com

Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.

Statera BioPharma (STU:7CB) Headlines

No Headlines